AUTHOR=Xia Haoran , Wang Miaomiao , Su Xiaonan , Lv Zhengtong , Yan Qiuxia , Guo Xiaoxiao , Liu Ming 

TITLE=A Novel Gene Signature Associated With “E2F Target” Pathway for Predicting the Prognosis of Prostate Cancer

JOURNAL=Frontiers in Molecular Biosciences

VOLUME=9

YEAR=2022

URL=https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2022.838654

DOI=10.3389/fmolb.2022.838654

ISSN=2296-889X

ABSTRACT=<p><bold>Background:</bold> The effect of the adenoviral early region 2 binding factors (E2Fs) target pathway on prostate cancer is not clear. It is necessary to establish an E2F target-related gene signature to predict prognosis and facilitate clinical decision-making.</p><p><bold>Methods:</bold> An E2F target-related gene signature was established by univariate and LASSO Cox regression analyses, and its predictive ability was verified in multiple cohorts. Moreover, the enrichment pathway, immune microenvironment, and drug sensitivity of the activated E2F target pathway were also explored.</p><p><bold>Results:</bold> The E2F target-related gene signature consisted of <italic>MXD3</italic>, <italic>PLK1</italic>, <italic>EPHA10</italic>, and <italic>KIF4A</italic>. The patients with high-risk scores showed poor prognosis, therapeutic resistance, and immunosuppression, along with abnormal growth characteristics of cells. Tinib drugs showed high sensitivity to the expression of <italic>MXD3</italic> and <italic>EPHA10</italic> genes.</p><p><bold>Conclusion:</bold> Our research established an E2F target-related signature for predicting the prognosis of prostate cancer. This study provides insights into formulating individualized detection and treatment as well as provides a theoretical basis for future research.</p>